Literature DB >> 6316156

A putative second cell-derived oncogene of the avian leukaemia retrovirus E26.

D Leprince, A Gegonne, J Coll, C de Taisne, A Schneeberger, C Lagrou, D Stehelin.   

Abstract

The acute avian leukaemia retroviruses AMV and E26 both induce myeloblastosis in vivo and transform myeloblasts in vitro. Both viruses contain the oncogene v-myb first described for AMV. Unlike AMV, E26 has the additional capacity to induce erythroblastosis in vivo and to transform erythroblasts. Previous analyses indicated that the genome of E26 also contained nucleotide sequences distinct from v-myb and unrelated to viral replicative genes. Using a molecularly cloned E26 provirus, we have now identified a novel nucleotide sequence designated v-ets (for E-twenty-six specific) of approximately 1.5 kilobase pairs (kbp) located next to v-myb. v-ets possesses all the structural characteristics of a putative new oncogene: it has a conserved cellular counterpart c-ets which is transcribed in some normal chicken cells as a major 7.5-kb polyadenylated RNA. Although our results now await elucidation of their biological significance, we propose that v-ets could be a new oncogene accounting for the additional transforming properties of E26, or potentiating the transforming properties of the v-myb oncogene.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6316156     DOI: 10.1038/306395a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  143 in total

1.  Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains.

Authors:  W Y Kim; M Sieweke; E Ogawa; H J Wee; U Englmeier; T Graf; Y Ito
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

2.  c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans.

Authors:  N Wernert; M B Raes; P Lassalle; M P Dehouck; B Gosselin; B Vandenbunder; D Stehelin
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

3.  An inhibitory carboxyl-terminal domain in Ets-1 and Ets-2 mediates differential binding of ETS family factors to promoter sequences of the mb-1 gene.

Authors:  J Hagman; R Grosschedl
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

4.  A positive regulator of the ribosomal protein gene, beta factor, belongs to the ETS oncoprotein family.

Authors:  T Yoganathan; N K Bhat; B H Sells
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

5.  The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism.

Authors:  Jason D Prescott; Karen S N Koto; Meenakshi Singh; Arthur Gutierrez-Hartmann
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  Two nuclear oncogenic proteins, P135gag-myb-ets and p61/63myc, cooperate to induce transformation of chicken neuroretina cells.

Authors:  P Amouyel; V Laudet; P Martin; R P Li; B Quatannens; D Stéhelin; S Saule
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

7.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

8.  TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation.

Authors:  Yutaka Morita; Chie Kanei-Ishii; Teruaki Nomura; Shunsuke Ishii
Journal:  Mol Biol Cell       Date:  2005-09-14       Impact factor: 4.138

9.  Expression of Ets-1 proto-oncoprotein in gastrointestinal stromal tumors, leiomyomas and schwannomas.

Authors:  Toshiyuki Nakayama; Ayumi Yoshizaki; Shinji Naito; Chun-Yang Wen; Gabit Alipov; Yuichi Yakata; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

Review 10.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.